论文信息 - Levetiracetam monotherapy in Alzheimer patients with late‐onset seizures: a prospective observational study

Levetiracetam monotherapy in Alzheimer patients with late‐onset seizures: a prospective observational study

Levetiracetam (LEV) monotherapy was investigated in 25 patients with advanced Alzheimer's disease (AD) and new‐onset epileptic seizures in a prospective open‐label study. At a daily dose of 1000–1500 mg, 72% were seizure‐free for at least one year; 16% discontinued for untolerability; 8% were unresponsive; 4% were lost to follow‐up. These results suggest the need for controlled studies to confirm if LEV can be a first‐choice drug in AD.

[1] F. Gilliam. Limitations of monotherapy trials in epilepsy , 2003, Neurology.

[2] K. Meador. Cognitive and memory effects of the new antiepileptic drugs , 2006, Epilepsy Research.

[3] N. Sethi,et al. COMPARISON OF LEVETIRACETAM AND CONTROLLED-RELEASE CARBAMAZEPINE IN NEWLY DIAGNOSED EPILEPSY , 2007, Neurology.

[4] Yaakov Stern,et al. Incidence and Predictors of Seizures in Patients with Alzheimer's Disease , 2006, Epilepsia.

[5] R. Ramsay,et al. Special considerations in treating the elderly patient with epilepsy , 2004, Neurology.

[6] C. Bucca,et al. Effects of Levetiracetam on Nocturnal Sleep and Daytime Vigilance in Healthy Volunteers , 2006, Epilepsia.

[7] J. Morris,et al. Advanced Alzheimer's disease is a risk factor for late-onset seizures. , 1990, Archives of neurology.

[8] E. Perucca. Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of Age , 2006, Clinical pharmacokinetics.

[9] D. Schmidt. Proof of principle trials: exploratory open studies , 2001, Epilepsy Research.

[10] I. Leppik. Epilepsy in the elderly. , 2006, Epilepsia.